A15

67. (Amended) A transgenic, cell tissue or organism according to claim 65, wherein said transgene is included in an expression vector according to claim 41.

A16

70. (Amended) A pharmaceutical composition comprising an antibody according to claim 68 together with a pharmaceutically acceptable carrier diluent or excipient therefor.

A17

72. (Amended) A nucleic acid molecule encoding a variant of a VEGF-X protein having a nucleotide sequence selected from the nucleotide sequences of Figure 12.

REMARKS

Claims 23, 53 and 8 have been canceled. The specification has been amended to incorporate the priority information for this Application. The claims have been amended solely for the purpose of removing multiple dependencies and aligning the claims to an acceptable claim format for U.S. examination. A substitute sequence listing has been provided along with a Computer Readable Form of the Sequence Listing. The undersigned hereby states that the Paper Copy and the Computer Readable Form are identical. No new matter has been added by these amendments. A version to show changes made accompanies this amendment. Favorable consideration of the remarks provided below is respectfully requested. Should the Examiner have any

questions he is invited to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Myra H. McCormack
Attorney for Applicants
Reg. No. 36,602

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
Dated: June 21, 2001

Version to show Changes Made

IN THE CLAIMS

3. (Amended) A nucleic acid molecule according to claim 1 [or 2] wherein said nucleic acid is a cDNA molecule.

5. (Amended) An antisense molecule capable of hybridising to a molecule according to [any of] claim[s] 1 [to 4] under high stringency conditions.

6. (Amended) A nucleic acid molecule according to [any of] claim[s] 1 [to 4] which is of mammalian origin.

9. (Amended) A VEGF-X protein, or a functional equivalent, derivative or bioprecusor thereof, encoded by a nucleic acid molecule as defined in [any of] claim[s] 1 [to 4].

10. (Amended) A VEFG-X protein comprising [A protein according to claim 9, which comprises] the amino acid sequence illustrated in Figure 10.

11. (Amended) An expression vector comprising a nucleic acid molecule according to [any of] claim[s] 1 [to 4].

14. (Amended) A pharmaceutical composition comprising a [A] nucleic acid molecule according to [any of] claim[s] 1 [to 4] or an antisense molecule according to claim 5 [for use as a medicament].

15. (Amended) A host cell transformed or transfected with an expression vector according to claim 11 [or 12].

17. (Amended) A transgenic cell, tissue or organism comprising a transgene capable of expressing a VEGF-X protein according to claim 8 [or 9].

21. (Amended) A process for producing a VEGF-X protein according to [any of] claim[s] 8 [to 10], said process comprising transforming a host cell or organism with an expression vector according to claim 11, and recovering the expressed protein from said host cell or organism.

22. (Amended) An antibody capable of binding to a protein according to [any of] claim[s] 8 [to 10], or an epitope thereof.

26. (Amended) A kit for identifying the presence of VEGF-X protein in a sample which comprises an antibody according to claim 22 [and means for contacting said antibody with said sample].

29. (Amended) A pharmaceutical composition comprising a [A] compound according to claim 28 for use as a medicament.

30. (Amended) A nucleic acid sequence selected from the group consisting of [comprising] the nucleotide sequences illustrated in any of Figures selected from the group of Figures comprising Figures 3, 5, 8 [or] and 13.

41. (Amended) A nucleic acid molecule according to claim 39 [or 40], comprising the nucleotide sequence from position 5 to 508 of the sequence illustrated in Figure 26.

42. (Amended) A nucleic acid molecule according to [any of] claim[s] 39 [to 41] comprising the nucleotide sequence illustrated in Figure 26.

44. (Amended) An expression vector comprising a nucleic acid molecule according to [any of] claim[s] 39 [to 42].

52. (Amended) A method of inhibiting angiogenic activity or inappropriate vascularisation, said method comprising contacting a cell expressing a VEGF receptor and a neuropilin type receptor with a protein selected from the group of [any of] a protein according to [any of] claim[s] 8 [to 10], [and] a protein according to claim 48, [or] and a protein according to claim 49.

55. (Amended) A nucleic acid molecule according to claim 54 wherein said sequence encoding said VEGF domain is selected from the sequences encoding any of VEGF A to D [or isoforms or variants thereof].

56. (Amended) A pharmaceutical composition comprising a [A] nucleic acid molecule encoding a polypeptide, the polypeptide having an amino acid sequence comprising the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10 [for use as a medicament].

57. (Amended) A method for treating [Use of a nucleic acid molecule encoding a polypeptide having the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10 in the manufacture of a medicament for treatment of] a disease condition[s] associated with inappropriate angiogenesis including [such as] tumour or cancer growth, retinopathy, osteoarthritis or psoriasis in a patient comprising

contacting the patient with a pharmaceutical composition comprising a nucleic acid molecule encoding a polypeptide having the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10.

59. (Amended) A method for treating [A polypeptide comprising the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10 in the manufacture of a medicament for the treatment of] a disease conditions associated with inappropriate angiogenesis such as tumour growth, retinopathy, osteoarthritis or psoriasis comprising contacting the patient with a polypeptide comprising the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10.

60. Use of a CUB domain comprising the amino acid sequence from position 40 to 150 of the sequence of Figure 10, or the amino acid sequence of Figure 26, to identify compounds which inhibit angiogenic activity in a method according to claim 50.

61. (Amended) A method of inhibiting angiogenic activity and inappropriate vascularisation including formation and proliferation of new blood vessels, growth and development of tissues, tissue regeneration and organ and tissue repair in a subject said method comprising administering to said subject an amount of a polypeptide having an amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10 or a nucleic acid molecule according to [any of] claim[s] 39 [to 42] in sufficient concentration to reduce or prevent said angiogenic activity.

62. (Amended) A method of treating or preventing any of cancer, rheumatoid arthritis, psoriasis and diabetic retinopathy, said method comprising administering to said subject an amount of a polypeptide having an amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10 or a nucleic acid molecule according to [any of] claim[s] 39 [to 42] in sufficient concentration to treat or prevent said disorders.

63. (Amended) An antisense molecule capable of hybridising to a molecule according to [any of] claim[s] 39 [to 42] under high stringency conditions.

67. (Amended) A transgenic, cell tissue or organism according to claim 65 [or 66], wherein said transgene is included in an expression vector according to claim 41 [or 42].

70. (Amended) A pharmaceutical composition comprising an antibody according to claim 68 [or 69] together with a pharmaceutically acceptable carrier diluent or excipient therefor.

72. (Amended) A nucleic acid molecule encoding a variant of a VEGF-X protein having <u>a</u> [any of the] <u>nucleotide</u> sequence[s] selected from the nucleotide sequences of [of nucleotides illustrated in] Figure 12.